Baseline characteristics of patients with RA in the main cohorts from five RA registries and one RA clinical trial programme
| Variable | Fostamatinib trials | CORRONA | SRR | NOAR | CORRONA International | IORRA | |
| (n=3240) | (n=24 176) | (n=18 527) | (n=1564) | (n=3867) | (n=10 255) | ||
| Demographic and RA disease characteristics, N (%)* | |||||||
| Sex | Male | 551 (17.0) | 5791 (24.0) | 5499 (29.7) | 470 (30.1) | 584 (15.1) | 1829 (17.8) |
| Female | 2689 (83.0) | 18 385 (76.0) | 13 028 (70.3) | 1094 (69.9) | 3283 (84.9) | 8426 (82.2) | |
| Age, years | <50 | 1174 (36.2) | 5973 (24.7) | 4268 (23.0) | 390 (24.9) | 1260 (32.6) | 3016 (29.4) |
| 50–<60 | 1123 (34.7) | 6777 (28.0) | 4235 (22.9) | 377 (24.1) | 1237 (32.0) | 3033 (29.6) | |
| 60–<70 | 712 (22.0) | 6302 (26.1) | 5084 (27.4) | 376 (24.0) | 933 (24.1) | 2727 (26.6) | |
| ≥70 | 231 (7.1) | 5124 (21.2) | 4940 (26.7) | 421 (26.9) | 437 (11.3) | 1479 (14.4) | |
| Race† | White | 2296 (80.5) | 21 654 (90.0) | NA | 1542 (99.2) | 2455 (66.2) | 0 (0.0) |
| Asian | 73 (2.6) | 372 (1.5) | NA | 4 (0.3) | 423 (11.4) | 10 255 (100.0) | |
| Black | 123 (4.3) | 1673 (7.0) | NA | 2 (0.1) | 34 (0.9) | 0 (0.0) | |
| Other | 361 (12.7) | 366 (1.5) | NA | 6 (0.4) | 799 (21.5) | 0 (0.0) | |
| Disease duration, years | <5 | 1200 (49.2) | 10 379 (43.2) | 12 962 (70.4) | 862 (55.1) | 1518 (39.4) | 4977 (48.5) |
| 5–<10 | 549 (22.5) | 4921 (20.5) | 1619 (8.8) | 474 (30.3) | 1021 (26.5) | 2078 (20.3) | |
| ≥10 | 688 (28.2) | 8742 (36.4) | 3819 (20.8) | 228 (14.6) | 1317 (34.2) | 3200 (31.2) | |
| DAS28 | <3.2 | 2 (0.1) | 4345 (41.7) | 3902 (24.1) | 168 (25.0) | 974 (31.5) | 2692 (29.5) |
| 3.2–<5.1 | 814 (25.2) | 4097 (39.3) | 6353 (39.2) | 339 (50.4) | 1260 (40.8) | 4825 (52.9) | |
| ≥5.1 | 2410 (74.7) | 1971 (18.9) | 5964 (36.8) | 166 (24.7) | 857 (27.7) | 1599 (17.5) | |
| HAQ score | <1.1 | 708 (21.9) | 15 018 (65.0) | 10 167 (60.8) | 699 (45.5) | 1791 (50.1) | 7131 (69.7) |
| 1.1–<1.8 | 1354 (41.9) | 6116 (26.5) | 4629 (27.7) | 443 (28.9) | 1101 (30.8) | 2095 (20.5) | |
| ≥1.8 | 1171 (36.2) | 1983 (8.6) | 1916 (11.5) | 393 (25.6) | 680 (19.0) | 1008 (9.8) | |
| RF+ | Yes | 2022 (78.0) | 9274 (72.4) | 12 904 (71.7) | 1103 (83.8) | 2679 (76.6) | 7683 (78.8) |
| CRP (mg/L) | <6 | 1182 (36.5) | 3368 (56.9) | 5106 (29.7) | 155 (21.2) | 976 (50.3) | 4895 (49.8) |
| 6–<10 | 549 (16.9) | 917 (15.5) | 3035 (17.6) | 121 (16.6) | 264 (13.6) | 1277 (13.0) | |
| 10–<16 | 483 (14.9) | 641 (10.8) | 2782 (16.2) | 145 (19.8) | 216 (11.1) | 1080 (11.0) | |
| ≥16 | 1026 (31.7) | 994 (16.8) | 6291 (36.5) | 310 (42.4) | 484 (24.9) | 2574 (26.2) | |
| ESR (mm/h) | <28 | 355 (11.3) | 7341 (66.8) | 10 511 (60.0) | NA | 1796 (58.1) | 4350 (44.4) |
| 28–<42 | 1394 (44.6) | 1801 (16.4) | 2995 (17.1) | NA | 586 (19.0) | 1918 (19.6) | |
| ≥42 | 1380 (44.1) | 1847 (16.8) | 4001 (22.9) | NA | 710 (23.0) | 3530 (36.0) | |
| Comorbidities (medical history), N (%)* | |||||||
| Diabetes | 260 (10.7) | 1883 (7.8) | 834 (4.5) | 129 (8.2) | 402 (10.4) | 246 (2.4) | |
| Coronary artery disease | 23 (0.9) | 1550 (6.4) | 1460 (7.9) | 40 (2.6) | 268 (6.9) | 152 (1.5) | |
| Hypertension | 977 (40.1) | 7455 (30.9) | 1866 (10.1) | 408 (26.1) | 1555 (40.2) | 772 (7.5) | |
| Peptic/bleeding ulcer | 1678 (6.9) | 456 (2.5) | 104 (6.6) | 209 (5.4) | 242 (2.4) | ||
| Liver disease | 1141 (4.7) | 124 (0.7) | 19 (1.2) | 93 (2.4) | 121 (1.2) | ||
| Assigned treatment (treatments used from baseline), N (%)* | |||||||
| Methotrexate | 2757 (85.1) | 15 609 (64.6) | 13 240 (71.5) | 528 (33.8) | 2684 (69.4) | 7664 (74.7) | |
| Other non-biological DMARD | 374 (11.5) | 7266 (30.1) | 4151 (22.4) | 379 (24.2) | 1893 (49.0) | 7818 (76.2) | |
| Biologicals | 4 (0.1) | 9217 (38.1) | 132 (0.7) | 15 (1.0) | 491 (12.7) | 1315 (12.8) | |
| Corticosteroids | 1735 (53.5) | 7214 (29.8) | 7933 (42.8) | 272 (17.4) | 1165 (30.1) | 6259 (61.0) | |
| NSAID/COX-2 | 2254 (69.6) | 11 709 (48.4) | 7764 (41.9) | 2426 (62.7) | 8947 (87.2) | ||
*Percentages were calculated based on non-missing data.
†Each patient is listed in only one category; patients who reported mixed race are coded in the first relevant category of the four listed.
CORRONA, Consortium of Rheumatology Researchers of North America; COX-2, cyclooxygenase-2 inhibitors; CRP, C reactive protein; DAS28, disease activity score in 28 joints (DAS28 in the NOAR registry is calculated from CRP); DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IORRA, Institute of Rheumatology Rheumatoid Arthritis; NA, not available; NOAR, Norfolk Arthritis Register; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis; RF+, rheumatoid factor positive; SRR, Swedish Rheumatology Quality of Care Register.